A Phase III Prospective Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Antagonist, ZD1839 (IRESSA) in Completely Resected Primary Stage IB, II and IIIA Non-Small Cell Lung Cancer

Closed

Published

Abbreviated Title

ZD1839/Stage IB, II & III NSCLC

Activated

11/01/2002

Closed

04/22/2005

Participants

CTSU

Research committees

Lung Cancer

Treatment

ZD1839

Eligibility Criteria Expand/Collapse

The Southwest Oncology Group participated in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for information.

Other Clinical Trials

SWOG Clinical Trial Number

A082002

A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer

Research Committee(s)

Lung Cancer

Activated

12/21/2021

Open

Phase

SWOG Clinical Trial Number

CTSU/NRG-LU007

RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial

Research Committee(s)

Lung Cancer

Activated

08/17/2020

Open

SWOG Clinical Trial Number

CTSU/A081801

Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

Research Committee(s)

Lung Cancer

Activated

06/23/2020

Open

Phase